Similarly, poor response to BRAF inhibitors in patients with BRAF-mutant melanoma has been correlated to concurrent loss-of-function mutations in the PTEN gene, which can lead to the reactivation of the PI3K/AKT pathway (226). This evidence concerns the gene PTEN and melanoma.